ANABNasdaqPharmaceutical PreparationsFiscal year ends June 30
ANAPTYSBIO, INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on May 12, 2026
$49.24+2.63 (+5.64%)
Close on Oct 19, 2026
- Market cap
- $2.28B
- P/E (TTM)
- –
- Dividend yield
- –
ANAPTYSBIO, INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Royalty Management | $234.60M | $91.28M | $17.16M | – | 100.0% | +157.0% |
| Biopharma | $0 | $0 | $0 | – | 0.0% | – |
| Reportable Segment | – | $91.28M | $17.16M | $10.29M | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | YoY |
|---|---|---|---|---|---|
| Royalty Management | $226.90M | $66.15M | -$45.95M | – | +243.0% |
| Biopharma | -$179.01M | -$181.10M | -$118.46M | – | -1.2% |
| Reportable Segment | – | -$114.95M | -$164.41M | -$115.15M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Anaptysbio's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.